Outlook on the Peptide Therapeutics Global Market to 2027 – Strategic Recommendations for New Entrants – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Peptide Therapeutics – Global Market Outlook (2019-2027)” report has been added to ResearchAndMarkets.com’s offering.

The Global Peptide Therapeutics market accounted for $28.15 billion in 2019 and is expected to reach $66.76 billion by 2027 growing at a CAGR of 11.4% during the forecast period.

Increasing prevalence of cancer, presence of strong product pipeline portfolio and an increasing number of cases of the metabolic disorder is driving market growth. However, stringent government regulation for the approval process is hampering the growth of the market.

Peptides represent one of a kind class of pharmaceutical compounds; it is recognized for being adequate and specific. Demand for peptides in clinical therapeutics is increasing as peptides have low production complexity as compared with that of protein-based biopharmaceuticals, which thereby reduces overall production cost.

Based on the type, the innovative segment is going to have high growth during the forecast period owing to the increasing investments by huge pharmaceuticals in R&D for the development of novel medicines and high prescription rate. By geography, Asia Pacific is going to have high growth during the forecast period owing to the vast patient pool, increasing healthcare expenditure and demand for newer advanced therapies.

Companies Mentioned

• Teva Pharmaceutical
• Bachem Holding AG

(Read more…)

• Sanofi
• Pfizer Inc.
• Amgen Inc.
• Novartis AG
• Lonza Inc.
• GlaxoSmithKline (GSK)
• Eli Lilly and Company
• Bristol-Myers Squibb(BMS)
• Merck & Co.
• AstraZeneca PLC
• Novo Nordisk A/S
• Ipsen
• Takeda Pharmaceutical Company Limited

What the report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company Profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Key Topics Covered:

1 Executive Summary

2 Preface

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Technology Analysis

3.7 Application Analysis

3.8 End User Analysis

3.9 Emerging Markets

3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Peptide Therapeutics Market, By Type

5.1 Introduction

5.2 Innovative

5.3 Generic

5.4 Branded

6 Global Peptide Therapeutics Market, By Type of Manufacturers

6.1 Introduction

6.2 Outsourced

6.3 In-house

6.4 Contract Manufacturing Organizations (CMOs)

7 Global Peptide Therapeutics Market, By Route of Administration

7.1 Introduction

7.2 Pulmonary

7.3 Parenteral

7.4 Oral

7.5 Mucosal

7.6 Injection

7.7 Other Route of Administrations

7.7.1 Nasal

7.7.2 Intradermal

8 Global Peptide Therapeutics Market, By Synthesis Technology

8.1 Introduction

8.2 Solid Phase Peptide Synthesis (SPPS)

8.3 Liquid Phase Peptide Synthesis (LPPS)

8.4 Hybrid Technology

9 Global Peptide Therapeutics Market, By Type of Molecule

9.1 Introduction

9.2 Vasopressin

9.3 Somatostatin

9.4 Natriuretic

9.5 Luteinizing Hormone (LH)-Releasing Hormone (LHRH)

9.6 Insulins

9.7 Immunopeptide

9.8 Glucagon and Analogs

9.9 Calcitonin

10 Global Peptide Therapeutics Market, By Application

10.1 Introduction

10.2 Cancer

10.2.1 Velcade (Bortezomib)

10.2.2 Zoladex (Goserelin)

10.2.3 Lupron/ Enantone/ Eligard (Leuprorelin)

10.3 Cardiovascular Disorder

10.3.1 Integrilin (Eptifibatide)

10.3.2 Angiomax (Bivalirudin)

10.4 Metabolic

10.4.1 Byetta (Exenatide)

10.4.2 Victoza (Liraglutide)

10.5 Respiratory

10.6 Gastro-Intestinal Infection (GIT)

10.6.1 Linzess (Linaclotide)

10.6.2 Gattex (Teduglutide)

10.7 Pain

10.8 Dermatology

10.9 Anti-infection

10.10 Central Nervous System

10.10.1 Copaxone (Glatiramer)

10.11 Renal

10.12 Infection

10.12.1 Victrelis (Boceprevir)

10.12.2 Incivek (Telaprevir)

10.13 Hematological Disorders

10.13.1 Kalbitor (Ecallantide)

10.13.2 Firazyr (Icatibant)

10.14 Acromegaly

10.15 Other Applications

10.15.1 Allergy/Immunological

10.15.2 Osteoporosis

11 Global Peptide Therapeutics Market, By End User

11.1 Introduction

11.2 Pharmaceutical and Biotechnology Industries

11.3 Hospitals

11.4 Contract Research Organization

11.5 Academic and Research Institutes

12 Global Peptide Therapeutics Market, By Geography

12.1 Introduction

12.2 North America

12.3 Europe

12.4 Asia Pacific

12.5 South America

12.6 Middle East & Africa

13 Key Developments

13.1 Agreements, Partnerships, Collaborations and Joint Ventures

13.2 Acquisitions & Mergers

13.3 New Product Launch

13.4 Expansions

13.5 Other Key Strategies

14 Company Profiling

For more information about this report visit https://www.researchandmarkets.com/r/w4f82s

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900